Equities analysts forecast that TAIWAN LIPOSOME/S (NASDAQ:TLC) will announce $560,000.00 in sales for the current quarter, Zacks Investment Research reports. Two analysts have made estimates for TAIWAN LIPOSOME/S’s earnings. The highest sales estimate is $610,000.00 and the lowest is $500,000.00. TAIWAN LIPOSOME/S posted sales of $570,000.00 during the same quarter last year, which would indicate a negative year-over-year growth rate of 1.8%. The business is scheduled to announce its next quarterly earnings report on Monday, April 6th.
According to Zacks, analysts expect that TAIWAN LIPOSOME/S will report full-year sales of $6.96 million for the current fiscal year, with estimates ranging from $6.88 million to $7.00 million. For the next financial year, analysts anticipate that the company will post sales of $2.20 million, with estimates ranging from $1.90 million to $2.50 million. Zacks’ sales averages are a mean average based on a survey of analysts that cover TAIWAN LIPOSOME/S.
TLC has been the topic of a number of research reports. HC Wainwright reaffirmed a “buy” rating and set a $10.00 target price on shares of TAIWAN LIPOSOME/S in a research note on Wednesday, October 23rd. ValuEngine upgraded shares of TAIWAN LIPOSOME/S from a “hold” rating to a “buy” rating in a research report on Tuesday. Zacks Investment Research raised shares of TAIWAN LIPOSOME/S from a “hold” rating to a “buy” rating and set a $5.75 price target for the company in a research note on Saturday, October 26th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of TAIWAN LIPOSOME/S in a report on Friday, October 18th. Seven research analysts have rated the stock with a buy rating, The company presently has a consensus rating of “Buy” and an average price target of $9.44.
A hedge fund recently raised its stake in TAIWAN LIPOSOME/S stock. Millennium Management LLC raised its holdings in shares of TAIWAN LIPOSOME/S (NASDAQ:TLC) by 564.6% in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 92,915 shares of the company’s stock after purchasing an additional 112,915 shares during the period. Millennium Management LLC owned 0.29% of TAIWAN LIPOSOME/S worth $474,000 as of its most recent SEC filing. 2.11% of the stock is currently owned by hedge funds and other institutional investors.
About TAIWAN LIPOSOME/S
Taiwan Liposome Company, Ltd., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of nanomedicines that combine its proprietary lipid-assembled drug delivery platform with approved active pharmaceutical ingredients (APIs). Its BioSeizer lipid formulation technology enables pharmacokinetic (PK) control and local sustained release of APIs at the site of disease or injury; and NanoX targeted delivery technology enables prolonged PK profiles and enhanced distribution of liposome-encapsulated APIs at the desired site.
Featured Story: Most Active Stocks: Dollar Volume vs Share Volume
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for TAIWAN LIPOSOME/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TAIWAN LIPOSOME/S and related companies with MarketBeat.com's FREE daily email newsletter.